

Brand Name: Vanticon

Generic: zafirlukast


Type: small molecule

Year Accepted/Phase: 1996

Mechanism:

Zafirlukast inhibits the action of leukotrienes by blocking their binding to leukotriene receptors, thereby reducing inflammation, bronchoconstriction, and mucus production in the airways.

Chemical Structure:



Indication:

Vanticon (zafirlukast) is indicated for the prophylaxis and chronic treatment of asthma in adults and children over the age of 5 years.

Clinical trials:

Clinical Trials for Asthma

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/8941502/>

Purpose: Evaluate the efficacy and safety of zafirlukast in the treatment of asthma.

Dates: Clinical trials for zafirlukast in asthma were conducted in the 1990s.

Results: These trials demonstrated that zafirlukast was effective in improving lung function, reducing asthma symptoms, and decreasing the need for rescue medication (such as short-acting beta-agonists).

Impact: The positive results from these trials supported the approval of zafirlukast for the treatment of asthma.